This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
Oncology NPs, PAs, and nurses
Assess evidence for novel therapies and combinations for HNSCC
Identify toxicities associated with novel and emerging therapies in HNSCC
Apply strategies to manage adverse events associated with therapies for HNSCC
All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Barbara Burtness, MD: consultant: ALX Oncology, Arvinas, AstraZeneca, Coherus, Cue Biopharma, Debio, Exelexis, Fusion, Genentech, GlaxoSmithKline, Hookipa, Merck KGaA, Nektar, Vaccinex; researcher: Cue Biopharma, Exelexis, Gilead, Merck, Vaccinex; data and safety monitoring committee: AstraZeneca/Medimmune, Kura, Nektar, Roche.
Beth Sandy, MSN, CRNP: consultant: Amgen, AstraZeneca, Janssen, Jazz, Merck, Takeda.
Susan Moench, PhD, PA-C: independent contractor: Gilead, Merck.
None of the members of the PCE or PACE staff have any relevant financial relationships to disclose.
Participants wishing to earn CE/CME credit must:
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: July 20, 2022
Expiration date: July 19, 2023
eNewsletter with interactive benchmarking and audio commentary
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until July 19, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Susan Moench, PhD, PA-C, Edison, New Jersey
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program has been made available online.